Identification

Name
Gabapentin
Accession Number
DB00996  (APRD00015)
Type
Small Molecule
Groups
Approved, Investigational
Description

Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain. Gabapentin is well tolerated in most patients, has a relatively mild side-effect profile, and passes through the body unmetabolized.

Structure
Thumb
Synonyms
  • 1-(Aminomethyl)cyclohexaneacetic acid
  • Gabapentin GR
  • Gabapentina
  • Gabapentine
  • Gabapentino
  • Gabapentinum
  • Gabapetin
External IDs
CI-945 / DM-1796 / GOE 3450 / GOE-3450
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act GabapentinCapsule100 mgOralActavis Pharma Company2005-02-16Not applicableCanada
Act GabapentinCapsule400 mgOralActavis Pharma Company2005-02-16Not applicableCanada
Act GabapentinCapsule300 mgOralActavis Pharma Company2005-02-16Not applicableCanada
Bci GabapentinCapsule300 mgOralBaker Cummins IncNot applicableNot applicableCanada
GabapentinCapsule100 mgOralSanis Health Inc2010-07-30Not applicableCanada
GabapentinCapsule300 mgOralSivem Pharmaceuticals Ulc2003-01-07Not applicableCanada
GabapentinCapsule300 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
GabapentinCapsule400 mgOralApotex CorporationNot applicableNot applicableCanada
GabapentinTablet600 mgOralSanis Health Inc2014-09-23Not applicableCanada
GabapentinCapsule400 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-gabapentinTablet600 mgOralApotex Corporation2008-06-04Not applicableCanada
Apo-gabapentinTablet800 mgOralApotex Corporation2008-06-04Not applicableCanada
Apo-gabapentin CapsulesCapsule400 mgOralApotex Corporation2001-08-27Not applicableCanada
Apo-gabapentin CapsulesCapsule300 mgOralApotex Corporation2001-08-27Not applicableCanada
Apo-gabapentin CapsulesCapsule100 mgOralApotex Corporation2001-08-27Not applicableCanada
Auro-gabapentinCapsule100 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Auro-gabapentinCapsule400 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Auro-gabapentinCapsule300 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Auro-gabapentin TabletsTablet600 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-gabapentin TabletsTablet800 mgOralAuro Pharma IncNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ACTIVE-PAC with GabapentinGabapentin (300 mg/1) + Lidocaine hydrochloride (4 g/100g) + Menthol (1 g/100g)KitN.O.R.T.H., Inc.2014-06-18Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dipentocaine Topical Cream Compounding KitGabapentin + Diclofenac sodium + Lidocaine hydrochlorideKitTopicalAlvix Laboratories2014-11-062018-03-12Us
FanatrexGabapentinKitOralCalifornia Pharmaceuticals, Llc2010-05-15Not applicableUs
FanatrexGabapentinKitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
Gapeam BudibacGabapentin + Amantadine hydrochloride + Baclofen + Bupivacaine hydrochloride + Cyclobenzaprine Hydrochloride + Diclofenac sodium + PentoxifyllineKitTopicalAlvix Laboratories2014-12-052018-03-14Us
SmartRx Gaba KitGabapentin + Lidocaine hydrochloride + MentholKitOral; TopicalMas Management Group Inc.2009-11-242018-04-11Us
SmartRx Gaba-V KitGabapentin + Capsaicin + Menthol + Methyl salicylateKitMas Management Group Inc2009-03-162018-04-11Us
Therapentin-60Gabapentin + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-05-172016-10-13Us
Therapentin-90Gabapentin + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-082016-10-13Us
Topical Nerve PainGabapentin (.1 g/100mL) + Diazepam (.1 g/100mL) + Diclofenac sodium (.1 g/100mL) + Ketamine (.1 g/100mL)CreamTopicalDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
International/Other Brands
Aclonium / Neurontin / Novo-Gabapentin
Categories
UNII
6CW7F3G59X
CAS number
60142-96-3
Weight
Average: 171.2368
Monoisotopic: 171.125928793
Chemical Formula
C9H17NO2
InChI Key
UGJMXCAKCUNAIE-UHFFFAOYSA-N
InChI
InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
IUPAC Name
2-[1-(aminomethyl)cyclohexyl]acetic acid
SMILES
NCC1(CC(O)=O)CCCCC1

Pharmacology

Indication

For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.

Associated Conditions
Pharmacodynamics

Gabapentin, an analog of GABA, is used as an anticonvulsant to treat partial seizures, amyotrophic lateral sclerosis (ALS), and painful neuropathies. Potential uses include monotherapy of refractory partial seizure disorders, and treatment of spasticity in multiple sclerosis, tremor. mood disorders, and attenuation of disruptive behaviors in dementia. Gabapentin has high lipid solubility, is not metabolized by the liver, has no protein binding, and doesn't possess the usual drug interactions.

Mechanism of action

Gabapentin interacts with cortical neurons at auxillary subunits of voltage-sensitive calcium channels. Gabapentin increases the synaptic concentration of GABA, enhances GABA responses at non-synaptic sites in neuronal tissues, and reduces the release of mono-amine neurotransmitters. One of the mechanisms implicated in this effect of gabapentin is the reduction of the axon excitability measured as an amplitude change of the presynaptic fibre volley (FV) in the CA1 area of the hippocampus. This is mediated through its binding to presynaptic NMDA receptors. Other studies have shown that the antihyperalgesic and antiallodynic effects of gabapentin are mediated by the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors. Gabapentin has also been shown to bind and activate the adenosine A1 receptor.

TargetActionsOrganism
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
AVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
UAdenosine receptor A1
agonist
Human
UNMDA receptor
inhibitor
Human
UGamma-aminobutyric acid type B receptor subunit 1Not AvailableHuman
UGamma-aminobutyric acid type B receptor subunit 2Not AvailableHuman
Absorption

Rapid. Absorbed in part by the L-amino acid transport system, which is a carrier-mediated, saturable transport system; as the dose increases, bioavailability decreases. Bioavailability ranges from approximately 60% for a 900 mg dose per day to approximately 27% for a 4800 milligram dose per day. Food has a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC).

Volume of distribution
  • 58±6 L
Protein binding

Less than 3% of gabapentin circulates bound to plasma protein.

Metabolism

All pharmacological actions following gabapentin administration are due to the activity of the parent compound; gabapentin is not appreciably metabolized in humans.

Route of elimination

Gabapentin is eliminated from the systemic circulation by renal excretion as unchanged drug. Gabapentin is not appreciably metabolized in humans.

Half life

5-7 hours

Clearance
  • 190 mL/min
Toxicity

Symptoms of overdose include ataxia, labored breathing, ptosis, sedation, hypoactivity, and excitation.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineGabapentin may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineGabapentin may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineGabapentin may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Gabapentin is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineGabapentin may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineGabapentin may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineGabapentin may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineGabapentin may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineGabapentin may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Gabapentin.Investigational
AcefyllineGabapentin may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Gabapentin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Acetylglycinamide chloral hydrate.Experimental
AcyclovirGabapentin may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alaproclate.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Gabapentin.Investigational
AlcuroniumGabapentin may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Gabapentin.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Gabapentin.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Allopregnanolone.Investigational
AlmasilateThe serum concentration of Gabapentin can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Almotriptan.Approved, Investigational
AloglutamolThe serum concentration of Gabapentin can be decreased when it is combined with Aloglutamol.Approved
AlosetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alprenolol.Approved, Withdrawn
AluminiumThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminium phosphateThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium phosphate.Approved, Investigational
Aluminum hydroxideThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AlverineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Gabapentin can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Gabapentin.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe metabolism of Gabapentin can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Gabapentin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BGabapentin may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Gabapentin can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aniracetam.Experimental
ApalutamideThe serum concentration of Gabapentin can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Gabapentin is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Gabapentin can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Gabapentin.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Gabapentin.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Gabapentin.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Gabapentin.Approved
AtazanavirThe metabolism of Gabapentin can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Atomoxetine.Approved
AtracuriumGabapentin may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateGabapentin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Azaperone.Investigational, Vet Approved
AzathioprineGabapentin may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when Gabapentin is combined with AZD-3043.Investigational
AzelastineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Gabapentin is combined with Baclofen.Approved
BamifyllineGabapentin may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe metabolism of Gabapentin can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Gabapentin can be increased when combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Gabapentin.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bifeprunox.Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Gabapentin.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Gabapentin.Approved
Bismuth subnitrateThe serum concentration of Gabapentin can be decreased when it is combined with Bismuth subnitrate.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Gabapentin.Approved
BL-1020The risk or severity of adverse effects can be increased when Gabapentin is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Gabapentin can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Gabapentin can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Gabapentin is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Gabapentin is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Gabapentin.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Gabapentin.Approved, Investigational
BromotheophyllineGabapentin may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Gabapentin.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bufotenine.Experimental, Illicit
BufyllineGabapentin may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Gabapentin.Investigational
BuprenorphineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Gabapentin is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butalbital.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Gabapentin.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cabergoline.Approved
CafedrineGabapentin may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineGabapentin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Calcium AcetateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe serum concentration of Gabapentin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Gabapentin can be decreased when it is combined with Calcium silicate.Experimental
CamazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Gabapentin is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Gabapentin can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Gabapentin.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Caroxazone.Withdrawn
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Gabapentin.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Gabapentin.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cathinone.Illicit
CeritinibThe serum concentration of Gabapentin can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Gabapentin.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorzoxazone.Approved
CilansetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cilansetron.Investigational
CimetidineThe serum concentration of Gabapentin can be increased when it is combined with Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumGabapentin may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram.Approved
ClarithromycinThe metabolism of Gabapentin can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gabapentin.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Gabapentin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Gabapentin.Approved
CobicistatThe metabolism of Gabapentin can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Gabapentin.Approved, Investigational
CrizotinibThe metabolism of Gabapentin can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Gabapentin can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Gabapentin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Gabapentin can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Gabapentin.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Gabapentin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Gabapentin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Gabapentin can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Gabapentin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Gabapentin can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Gabapentin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Gabapentin.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Gabapentin.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Gabapentin can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Gabapentin.Approved
DolasetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dotarizine.Investigational
DoxacuriumGabapentin may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Gabapentin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Gabapentin.Approved, Investigational
DoxofyllineGabapentin may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe metabolism of Gabapentin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Gabapentin is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Gabapentin.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dyclonine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Gabapentin.Approved
EcopipamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Edivoxetine.Investigational
EfavirenzThe serum concentration of Gabapentin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Gabapentin.Approved
EletriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Entacapone.Approved, Investigational
EntecavirGabapentin may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EnzalutamideThe serum concentration of Gabapentin can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ergonovine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Gabapentin.Approved
ErythromycinThe metabolism of Gabapentin can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gabapentin.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etacrynic acid.Approved, Investigational
EtamiphyllineGabapentin may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethadione.Experimental
EthanolGabapentin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Gabapentin can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenethyllineGabapentin may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Gabapentin.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Gabapentin can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Gabapentin.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Gabapentin.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Gabapentin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Gabapentin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Gabapentin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Frovatriptan.Approved, Investigational
FurafyllineGabapentin may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Gabapentin can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gaboxadol.Investigational
GallamineGabapentin may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideGabapentin may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GanciclovirGabapentin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Gabapentin is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Gabapentin.Approved, Investigational
GranisetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.Approved, Investigational
GuanineGabapentin may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hexapropymate.Experimental
HexobarbitalThe metabolism of Gabapentin can be increased when combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hydracarbazine.Experimental
HydrocodoneGabapentin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.Approved, Illicit
HydrotalciteThe serum concentration of Gabapentin can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hypericin.Investigational
HypoxanthineGabapentin may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Gabapentin can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Gabapentin.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Imagabalin.Investigational
ImatinibThe metabolism of Gabapentin can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Gabapentin.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Gabapentin can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Gabapentin.Withdrawn
IprazochromeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Gabapentin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Gabapentin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Isepamicin.Experimental
IsocarboxazidThe therapeutic efficacy of Gabapentin can be increased when used in combination with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Gabapentin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Gabapentin.Approved, Vet Approved
IsoniazidThe metabolism of Gabapentin can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Gabapentin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Gabapentin can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketamine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Gabapentin can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Gabapentin is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Gabapentin.Approved
LacosamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Gabapentin.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Gabapentin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gabapentin.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Gabapentin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Linezolid.Approved, Investigational
LisofyllineGabapentin may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium cation.Experimental
LobucavirGabapentin may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Gabapentin can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Gabapentin can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Gabapentin can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lortalamine.Experimental
LovastatinThe metabolism of Gabapentin can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Gabapentin.Approved, Investigational
LuliconazoleThe serum concentration of Gabapentin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Gabapentin can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with m-Chlorophenylpiperazine.Investigational
MagaldrateThe serum concentration of Gabapentin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium acetateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium orotate.Experimental
Magnesium oxideThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Gabapentin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium Trisilicate.Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Gabapentin.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Maprotiline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Medifoxamine.Experimental
MefloquineThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Gabapentin is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Gabapentin is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Melperone.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe metabolism of Gabapentin can be increased when combined with Methohexital.Approved
MethotrimeprazineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Gabapentin.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Gabapentin can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methysergide.Approved
MetocurineGabapentin may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideGabapentin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetyrosineGabapentin may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe metabolism of Gabapentin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Gabapentin can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Gabapentin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Gabapentin is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Gabapentin.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
MirtazapineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Gabapentin can be decreased when it is combined with Mitotane.Approved
MivacuriumGabapentin may increase the neuromuscular blocking activities of Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Gabapentin is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Gabapentin is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Gabapentin can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Gabapentin is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
NafcillinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Gabapentin is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin.Approved
NaloxoneThe metabolism of Gabapentin can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nefiracetam.Investigational
NelfinavirThe metabolism of Gabapentin can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Gabapentin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Gabapentin can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Niaprazine.Experimental
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Gabapentin.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Gabapentin.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Gabapentin.Experimental
NilotinibThe metabolism of Gabapentin can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrazepam.Approved
NitroprussideGabapentin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrous oxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Gabapentin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Gabapentin.Approved, Investigational
OlaparibThe metabolism of Gabapentin can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Olopatadine.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Gabapentin.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Gabapentin is combined with Opium.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Gabapentin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineGabapentin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Gabapentin is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Gabapentin is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Gabapentin can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxcarbazepine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Gabapentin.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxprenolol.Approved
OxtriphyllineGabapentin may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxypertine.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Gabapentin.Investigational, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Gabapentin can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Gabapentin.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Palonosetron.Approved, Investigational
PancuroniumGabapentin may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeGabapentin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.Approved, Investigational
PeldesineGabapentin may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedGabapentin may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Gabapentin is combined with Penbutolol.Approved, Investigational
PenciclovirGabapentin may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Gabapentin.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.Approved, Vet Approved
PentifyllineGabapentin may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe metabolism of Gabapentin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineGabapentin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
PerazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Gabapentin.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Gabapentin can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Gabapentin.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Gabapentin.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phentermine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Gabapentin.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Gabapentin.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gabapentin.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipamperone.Approved, Investigational
PipecuroniumGabapentin may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pirlindole.Approved
PitolisantThe serum concentration of Gabapentin can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Gabapentin.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Gabapentin.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Gabapentin.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Gabapentin.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Gabapentin.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Gabapentin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Gabapentin.Approved, Investigational
PramipexoleGabapentin may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Gabapentin.Approved
PregabalinThe therapeutic efficacy of Gabapentin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pridinol.Experimental
PrimidoneThe metabolism of Gabapentin can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Gabapentin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Gabapentin is combined with Propanidid.Experimental
PropentofyllineGabapentin may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Gabapentin.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Gabapentin.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Gabapentin.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Gabapentin is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Proxibarbal.Experimental
ProxyphyllineGabapentin may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Gabapentin.Approved
PRX-08066The risk or severity of adverse effects can be increased when Gabapentin is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Gabapentin.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Gabapentin.Approved, Investigational
QuinineThe metabolism of Gabapentin can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ramosetron.Approved, Investigational
RapacuroniumGabapentin may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Rasagiline.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Gabapentin.Investigational
ReboxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Gabapentin can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Gabapentin can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Gabapentin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Gabapentin can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Gabapentin can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Gabapentin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ritanserin.Investigational
RitonavirThe metabolism of Gabapentin can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Rizatriptan.Approved
RocuroniumGabapentin may increase the neuromuscular blocking activities of Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Gabapentin is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Romifidine.Vet Approved
RopiniroleGabapentin may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineGabapentin may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Gabapentin is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Gabapentin.Approved
SafinamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Gabapentin can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Gabapentin is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Gabapentin can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Gabapentin.Approved
SerotoninThe risk or severity of adverse effects can be increased when Gabapentin is combined with Serotonin.Investigational, Nutraceutical
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Gabapentin.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Gabapentin.Approved
SiltuximabThe serum concentration of Gabapentin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Gabapentin can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sisomicin.Investigational
Sodium bicarbonateThe serum concentration of Gabapentin can be decreased when it is combined with Sodium bicarbonate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Gabapentin.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Gabapentin.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Gabapentin.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Gabapentin.Approved
St. John's WortThe serum concentration of Gabapentin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Gabapentin can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Gabapentin.Approved
SulpirideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sumatriptan.Approved, Investigational
SuvorexantGabapentin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Gabapentin is combined with Talopram.Experimental
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Gabapentin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Gabapentin is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Gabapentin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Gabapentin can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Gabapentin.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Gabapentin.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrodotoxin.Investigational
ThalidomideGabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineGabapentin may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineGabapentin may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe metabolism of Gabapentin can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe metabolism of Gabapentin can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Gabapentin.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Gabapentin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Gabapentin.Approved
TipranavirThe metabolism of Gabapentin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Gabapentin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tofisopam.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Gabapentin.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Gabapentin.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Gabapentin.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Gabapentin.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trimethadione.Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Gabapentin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triprolidine.Approved
TroleandomycinThe metabolism of Gabapentin can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tropisetron.Approved, Investigational
TubocurarineGabapentin may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Gabapentin.Investigational
Uric AcidGabapentin may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vabicaserin.Investigational
ValaciclovirGabapentin may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Gabapentin is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirGabapentin may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Valnoctamide.Investigational
ValomaciclovirGabapentin may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Gabapentin is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vancomycin.Approved
VecuroniumGabapentin may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gabapentin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Gabapentin.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vinylbital.Experimental
VoriconazoleThe metabolism of Gabapentin can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Gabapentin is combined with Wortmannin.Experimental
XanthineGabapentin may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Gabapentin is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Gabapentin is combined with YKP-1358.Investigational
YohimbineThe therapeutic efficacy of Gabapentin can be increased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Gabapentin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zolmitriptan.Approved, Investigational
ZolpidemGabapentin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Gabapentin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Donald E. Butler, Barbara J. Greenman, "Gabapentin mohohydrate and a process for producing the same." U.S. Patent US4960931, issued May, 1978.

US4960931
General References
  1. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S: Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2):119-28. [PubMed:11251695]
  2. Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med. 2004 Mar;5 Suppl 1:S28-47. [PubMed:14996228]
  3. Choudhuri I, Sarvananthan N, Gottlob I: Survey of management of acquired nystagmus in the United Kingdom. Eye (Lond). 2007 Sep;21(9):1194-7. Epub 2006 May 26. [PubMed:16732211]
  4. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000 Sep;2(3 Pt 2):249-55. [PubMed:11249802]
  5. Su TZ, Feng MR, Weber ML: Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15. Epub 2005 Mar 15. [PubMed:15769862]
External Links
Human Metabolome Database
HMDB0005015
KEGG Drug
D00332
PubChem Compound
3446
PubChem Substance
46506529
ChemSpider
3328
BindingDB
50080153
ChEBI
42797
ChEMBL
CHEMBL940
Therapeutic Targets Database
DNC000670
PharmGKB
PA449720
HET
GBN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Gabapentin
ATC Codes
N03AX12 — Gabapentin
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
PDB Entries
2a1h / 2coi / 2coj / 2ej3
FDA label
Download (1.5 MB)
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingOtherAutism Spectrum Conditions/Disorders1
0RecruitingTreatmentCentral Centrifugal Cicatricial Alopecia / Central Centrifugal Scarring Alopecia / Frontal Fibrosing Alopecia / Lichen Planopilaris / Scarring Alopecia1
0RecruitingTreatmentLumbar Spinal Instability / Lumbar Spine Degeneration / Spinal Stenosis of Lumbar Region1
0RecruitingTreatmentPain, Acute1
0WithdrawnTreatmentTourniquet-induced Hypertension / Tourniquet-induced Pain1
1Active Not RecruitingPreventionOpioids Use / Postoperative pain1
1CompletedNot AvailableDrug Dependence1
1CompletedNot AvailableHealthy Volunteers7
1CompletedOtherEpilepsies1
1CompletedPreventionPreterm Labor, Premature Birth1
1CompletedTreatmentDrug Usage1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentSleeplessness1
1WithdrawnTreatmentPruritus1
1, 2CompletedPreventionFeeling Anxious / Pain1
1, 2RecruitingNot AvailableClinical High Risk for Psychosis1
2Active Not RecruitingTreatmentAlcohol Use Disorder (AUD) / Alcohol Withdrawal Syndrome(AWS)1
2Active Not RecruitingTreatmentIrritability / Neurologically Impaired / Pain, Chronic / Signs and Symptoms, Digestive / Sleeplessness1
2Active Not RecruitingTreatmentMenopausal Hot Flushes1
2CompletedSupportive CareAcute Lymphoblastic Leukaemias (ALL) / Neuropathy / Pain, Neuropathic1
2CompletedSupportive CareMucositis1
2CompletedTreatmentAlcohol Dependence / Alcoholism1
2CompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentBenzodiazepine Dependence / Opioid Dependence1
2CompletedTreatmentCannabis Dependence1
2CompletedTreatmentCannabis Dependence / Cannabis Withdrawal / Cognitive Deficits1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentDependence, Cocaine / Depressive Symptoms1
2CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
2CompletedTreatmentMenopausal Hot Flushes1
2CompletedTreatmentNerve Pain / Neuropathy / Post-Herpetic Neuralgia (PHN)1
2CompletedTreatmentOpiate withdrawal symptoms / Opioid Dependence / Opioid Detoxification1
2CompletedTreatmentOpioid-Induced Hyperalgesia1
2CompletedTreatmentPendular Nystagmus Patients With Multiple Sclerosis1
2CompletedTreatmentPost-traumatic Neuropathic Pain1
2CompletedTreatmentPostoperative Complications1
2CompletedTreatmentSickle Cell Disorders1
2CompletedTreatmentSleep Initiation and Maintenance Disorders1
2CompletedTreatmentSmoking, Cigarette / Tobacco Use1
2CompletedTreatmentTinnitus1
2Not Yet RecruitingBasic ScienceAlcohol Use Disorder (AUD) / Opioid-use Disorder1
2Not Yet RecruitingTreatmentPain, Chronic1
2RecruitingBasic ScienceAlcohol Use Disorder (AUD) / Bipolar Disorder (BD)1
2RecruitingBasic ScienceBipolar I Disorder / Bipolar II Disorder / Cannabis Use Disorders / Substance Use Disorder (SUD)1
2RecruitingSupportive CareCancer of the Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingSupportive CareHPV-Related Squamous Cell Carcinoma / Oropharyngeal Cancers1
2RecruitingTreatmentOther Abortion / Spontaneous Abortions1
2TerminatedTreatmentBenzodiazepine Dependence1
2TerminatedTreatmentProstate Cancer1
2Unknown StatusTreatmentIntervertebral Disc Displacement / Intervertebral Disc Herniation1
2Unknown StatusTreatmentTinnitus, Subjective1
2WithdrawnTreatmentFabry's Disease / Pain, Neuropathic1
2, 3CompletedPreventionEffect of Laryngoscopy and Tracheal Intubation1
2, 3CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2, 3CompletedTreatmentAlcohol Dependence2
2, 3CompletedTreatmentDetrusor Uninhibited Activity / Incontinence / Nocturia / Quality of Life / Urinary Frequency / Urination urgency of1
2, 3CompletedTreatmentFemale Genital Diseases1
2, 3CompletedTreatmentFibromyalgia1
2, 3Not Yet RecruitingTreatmentAnterior Cruciate Ligament Rupture / Muscle Weakness1
2, 3Not Yet RecruitingTreatmentArthralgia / Breast Cancer Invasive Nos / Chemotherapeutic Toxicity / Muscle Soreness1
2, 3RecruitingSupportive CareBladder Carcinoma1
2, 3RecruitingTreatmentDrug Dependence1
2, 3TerminatedTreatmentAnalgesia / Inguinal Hernias / Pain1
2, 3TerminatedTreatmentTinnitus1
3Active Not RecruitingTreatmentPain1
3Active Not RecruitingTreatmentPain / Quality of Life1
3CompletedNot AvailableSeizures1
3CompletedPreventionPostoperative pain1
3CompletedSupportive CareCancer, Breast / Menopausal Hot Flushes2
3CompletedSupportive CareIntervertebral Disc Herniation1
3CompletedSupportive CareMenopausal Hot Flushes / Prostate Cancer1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedSupportive CareNeurotoxicity / Pain1
3CompletedTreatmentCarpal Tunnel Syndrome (CTS)2
3CompletedTreatmentCholestasis / Itching / Liver Cirrhosis / Liver Diseases / Pruritus1
3CompletedTreatmentCisplatin Adverse Reaction / Vomiting1
3CompletedTreatmentDiabetic Neuropathies / Polyneuropathies1
3CompletedTreatmentEpilepsy, Localization Related2
3CompletedTreatmentFibromyalgia1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentMenopausal Hot Flushes3
3CompletedTreatmentMenopausal Hot Flushes / Menopause1
3CompletedTreatmentPost-Operative Pain1
3CompletedTreatmentPostherpetic Neuralgia1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentScoliosis1
3CompletedTreatmentTransient Insomnia7
3Not Yet RecruitingPreventionHerpetic Neuralgia1
3Not Yet RecruitingTreatmentBladder Pain Syndrome / Interstitial Cystitis1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
3RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingSupportive CareOropharynx Cancers1
3RecruitingTreatmentHyperemesis Gravidarum1
3RecruitingTreatmentPain, Chronic1
3RecruitingTreatmentPain, Chronic / Postoperative pain1
3RecruitingTreatmentPelvic Organ Prolapse (POP)1
3RecruitingTreatmentPelvic Pain1
3TerminatedNot AvailableNeuroleptic-Induced Tremor1
3TerminatedSupportive CareCancer, Breast / Lung Cancers / Pain1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentFunctional Dyspepsia1
3WithdrawnPreventionPost-thoracotomy Pain1
4Active Not RecruitingTreatmentPeripheral Nerve Disorder Associated With Repair of Hernia1
4CompletedNot AvailableEpilepsy, Localization Related1
4CompletedBasic ScienceOsteoarthritis (OA)1
4CompletedBasic ScienceSleeplessness1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionPostoperative pain1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedSupportive CarePain1
4CompletedSupportive CarePain After Photorefractive Keratectomy1
4CompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
4CompletedTreatmentAmputation of Lower Limb1
4CompletedTreatmentAnalgesia / Postoperative pain1
4CompletedTreatmentAneurysmal Subarachnoid Hemorrhage1
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentCardiopulmonary Bypass1
4CompletedTreatmentCarpal Tunnel Syndrome (CTS) / Complex Regional Pain Syndrome (CRPS) / Diabetic Neuropathies / HIV Neuropathy / Idiopathic Sensory Neuropathy / Peripheral Neuropathy / Postherpetic Neuralgia1
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentComplex Partial Seizure Disorder / Epilepsies / Epilepsy, Localization Related / Partial Seizure Disorder1
4CompletedTreatmentDiabetic Neuropathies2
4CompletedTreatmentDiabetic Neuropathy, Painful1
4CompletedTreatmentDiabetic Peripheral Neuropathic Pain1
4CompletedTreatmentEpilepsies / Pain, Chronic1
4CompletedTreatmentEpilepsy, Localization Related1
4CompletedTreatmentHead and Neck Carcinoma / Pain, Acute / Postoperative pain1
4CompletedTreatmentHerpes Zoster / Pain / Postherpetic Neuralgia1
4CompletedTreatmentLaparoscopic Cholecystectomy / Postoperative pain1
4CompletedTreatmentMenopausal Hot Flushes1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNeuropathy / Pain1
4CompletedTreatmentOculopalatal Tremor / Pendular Nystagmus1
4CompletedTreatmentOrthopedic Disorders / Postoperative pain1
4CompletedTreatmentParesthesia / Thoracic Pain1
4CompletedTreatmentPostoperative pain / Postoperative Sedation1
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentProstate Cancer1
4Enrolling by InvitationPreventionPostoperative pain1
4Enrolling by InvitationTreatmentDiabetic Neuropathy, Painful / Pain, Neuropathic / Type 2 Diabetes Mellitus1
4Enrolling by InvitationTreatmentNonspecific Pain Post Traumatic Injury1
4Not Yet RecruitingTreatmentChronic Pain Syndrome / Opioids Use / Postpartum disorder1
4Not Yet RecruitingTreatmentFacial Pain / Pain, Acute / Postoperative pain1
4Not Yet RecruitingTreatmentKnee Osteoarthritis (Knee OA) / Knee Pain Chronic / Opioid Dependence / Opioids Use1
4Not Yet RecruitingTreatmentPostoperative pain2
4Not Yet RecruitingTreatmentPostoperative pain / Renal Stones1
4RecruitingHealth Services ResearchTonsillectomy / Tonsillitis1
4RecruitingPreventionAnaesthesia therapy / Urethral Obstruction1
4RecruitingPreventionPelvic Organ Prolapse (POP)1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentAlcohol Dependence1
4RecruitingTreatmentAlcohol Withdrawal Syndrome(AWS)1
4RecruitingTreatmentCervical Preparation / Pain / Pregnancy Termination1
4RecruitingTreatmentCesarean Delivery / Pain Management1
4RecruitingTreatmentKnee Replacement Surgery / Pain1
4RecruitingTreatmentMyofacial Pain1
4RecruitingTreatmentPain2
4RecruitingTreatmentPain Management1
4RecruitingTreatmentPost-laminectomy Pain Syndrome1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentPostoperative pain / Surgery, Thoracic1
4RecruitingTreatmentRib Fracture Multiple / Rib Fractures1
4TerminatedTreatmentAbdominal Pain (AP) / Surgical Adhesions1
4TerminatedTreatmentChronic Low Back Pain (CLBP) / Diabetic Neuropathic Pain1
4TerminatedTreatmentDegenerative Joint Disease of Hip and Knee1
4TerminatedTreatmentImpaired Renal Function1
4TerminatedTreatmentInterstitial Cystitis / Irritable Bowel Syndrome (IBS) / Pelvic Pain / Prostatitis / Ulcerative Colitis (UC)1
4TerminatedTreatmentNeuropathic Chronic Pain1
4TerminatedTreatmentPK Properties Of Gabapentin In Subjects With Impaired Renal Function1
4TerminatedTreatmentPain1
4TerminatedTreatmentPostoperative pain1
4TerminatedTreatmentRestless Legs Syndrome (RLS)1
4TerminatedTreatmentSleep1
4Unknown StatusTreatmentCholecystolithiasis1
4Unknown StatusTreatmentHyperalgesia1
4Unknown StatusTreatmentPlanned Abdominal Hysterectomy1
4WithdrawnPreventionKnee Arthroscopy / Shoulder Arthroscopy1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Depression / Menopausal Hot Flushes / Psychosocial Effects of Cancer and Its Treatment1
Not AvailableActive Not RecruitingOtherPain1
Not AvailableActive Not RecruitingSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain / Vesicular Stomatitis1
Not AvailableCompletedNot AvailableAcute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableCompletedNot AvailableEpilepsy, Localization Related1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedOtherAlcohol Dependence / Sleeplessness1
Not AvailableCompletedPreventionPruritus1
Not AvailableCompletedSupportive CareAnxiety Disorders / Cancer, Breast / Depression / Menopausal Hot Flushes1
Not AvailableCompletedSupportive CareTotal Knee Arthroplasty (TKA)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedTreatmentAnal Condyloma / Fissure in Ano / Hemorrhoids / Rectal Fistulas1
Not AvailableCompletedTreatmentBurn Injuries / Pain1
Not AvailableCompletedTreatmentCerebral Tumors1
Not AvailableCompletedTreatmentChronic Pelvic Pain1
Not AvailableCompletedTreatmentFibromyalgia1
Not AvailableCompletedTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableCompletedTreatmentHyperalgesia / Opioid-Related Disorders1
Not AvailableCompletedTreatmentKnee Replacement Surgery / Post Operative Pain1
Not AvailableCompletedTreatmentMenopausal Hot Flushes / Menopause / Vasomotor Disturbance1
Not AvailableCompletedTreatmentNystagmus / Nystagmus, Pathological1
Not AvailableCompletedTreatmentPain4
Not AvailableCompletedTreatmentPost Operative Pain Management in Children With Tonsillectomy/Adenoidectomy1
Not AvailableCompletedTreatmentPostoperative pain3
Not AvailableCompletedTreatmentPostoperative pain / Total Hip Replacement1
Not AvailableCompletedTreatmentRadicular syndrome / Sciatica1
Not AvailableCompletedTreatmentSedation, Conscious1
Not AvailableCompletedTreatmentSleep Bruxism1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentVulvodynia1
Not AvailableNot Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableNot Yet RecruitingTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableNot Yet RecruitingTreatmentSurgery, Cardiac1
Not AvailableRecruitingSupportive CareStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v81
Not AvailableRecruitingTreatmentAmputations / Phantom Pain Following Amputation of Lower Limb1
Not AvailableRecruitingTreatmentEmergence Agitation After Desflurane Anesthesia1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableTerminatedTreatmentComplex Regional Pain Syndrome I (CRPS I)1
Not AvailableTerminatedTreatmentPain1
Not AvailableTerminatedTreatmentPostoperative pain1
Not AvailableTerminatedTreatmentVulvar Pain Symptoms / Vulvar Vestibulitis Syndrome (Chronic Vulvar Pain Localized to the Vaginal Opening) / Vulvodynia (Chronic Vulvar Pain)1
Not AvailableUnknown StatusTreatmentObesity, Morbid / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
Not AvailableUnknown StatusTreatmentPediatric Chronic Neuropathic Pain1
Not AvailableUnknown StatusTreatmentPruritus / Uremia1
Not AvailableWithdrawnNot AvailablePain1
Not AvailableWithdrawnTreatmentCardiovascular Health / Vasomotor Symptoms1

Pharmacoeconomics

Manufacturers
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Aurobindo pharma usa inc
  • Hikma pharmaceuticals
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Pfizer pharmaceuticals ltd
  • Parke davis div warner lambert co
  • Glenmark generics ltd
  • Matrix laboratories ltd
  • Teva pharmaceuticals usa inc
Packagers
  • 4uOrtho LLC
  • Actavis Group
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Blenheim Pharmacal
  • Blu Pharmaceuticals LLC
  • Bryant Ranch Prepack
  • Camber Pharmaceuticals Inc.
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Fusion Pharmaceuticals LLC
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hikma Pharmaceuticals
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Living Well Pharmacy Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Packaging Center
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Professional Co.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vangard Labs Inc.
  • Warner Lambert Company LLC
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
KitOral
CapsuleOral100 mg/1
CapsuleOral300 mg/300mg
CapsuleOral300 mg/1
CapsuleOral400 mg/1
CapsuleOral600 mg/1
SolutionOral250 mg/5mL
SuspensionOral250 mg/5mL
TabletOral600 mg/1
TabletOral800 mg/1
TabletOral800 mg/800mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral600 mg/1001
Tablet, film coatedOral600 mg/1
Tablet, film coatedOral800 mg/1
Kit
Tablet, multilayer, extended releaseOral600 mg
Tablet, multilayer, extended releaseOral800 mg
KitTopical
TabletOral600 mg
TabletOral800 mg
CapsuleOral100 mg
CapsuleOral300 mg
CapsuleOral400 mg
KitOral; Topical
Kit
CreamTopical
Prices
Unit descriptionCostUnit
Gabapentin powder30.0USD g
Neurontin 800 mg tablet4.73USD tablet
Neurontin 600 mg tablet3.94USD tablet
Gabapentin 800 mg tablet3.09USD tablet
Gabapentin 600 mg tablet2.58USD tablet
Neurontin 400 mg Capsule1.97USD capsule
Neurontin 300 mg Capsule1.67USD capsule
Gabapentin 400 mg tablet1.59USD tablet
Gabapentin 300 mg tablet1.32USD tablet
Gabapentin 400 mg Capsule1.21USD capsule
Gabapentin 300 mg Capsule1.02USD capsule
Apo-Gabapentin 400 mg Capsule0.76USD capsule
Co Gabapentin 400 mg Capsule0.76USD capsule
Mylan-Gabapentin 400 mg Capsule0.76USD capsule
Novo-Gabapentin 400 mg Capsule0.76USD capsule
Phl-Gabapentin 400 mg Capsule0.76USD capsule
Pms-Gabapentin 400 mg Capsule0.76USD capsule
Ran-Gabapentin 400 mg Capsule0.76USD capsule
Ratio-Gabapentin 400 mg Capsule0.76USD capsule
Neurontin 100 mg Capsule0.65USD capsule
Apo-Gabapentin 300 mg Capsule0.64USD capsule
Co Gabapentin 300 mg Capsule0.64USD capsule
Mylan-Gabapentin 300 mg Capsule0.64USD capsule
Novo-Gabapentin 300 mg Capsule0.64USD capsule
Phl-Gabapentin 300 mg Capsule0.64USD capsule
Pms-Gabapentin 300 mg Capsule0.64USD capsule
Ran-Gabapentin 300 mg Capsule0.64USD capsule
Ratio-Gabapentin 300 mg Capsule0.64USD capsule
Gabapentin 100 mg tablet0.53USD tablet
Gabapentin 100 mg Capsule0.41USD capsule
Neurontin 250 mg/5ml Solution0.32USD ml
Apo-Gabapentin 100 mg Capsule0.26USD capsule
Co Gabapentin 100 mg Capsule0.26USD capsule
Mylan-Gabapentin 100 mg Capsule0.26USD capsule
Novo-Gabapentin 100 mg Capsule0.26USD capsule
Phl-Gabapentin 100 mg Capsule0.26USD capsule
Pms-Gabapentin 100 mg Capsule0.26USD capsule
Ran-Gabapentin 100 mg Capsule0.26USD capsule
Ratio-Gabapentin 100 mg Capsule0.26USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2327285No2005-06-142019-05-10Canada
CA2215923No2001-10-092016-04-26Canada
US6054482Yes1997-10-252017-10-25Us
US7256216Yes2002-11-282022-11-28Us
US6340475No1996-09-192016-09-19Us
US6635280No1996-09-192016-09-19Us
US6488962No2000-06-202020-06-20Us
US6723340No2001-10-252021-10-25Us
US7438927No2004-02-262024-02-26Us
US8192756No2002-10-252022-10-25Us
US8252332No2002-10-252022-10-25Us
US8333992No2002-10-252022-10-25Us
US7731989No2002-10-252022-10-25Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)162-166 °CNot Available
water solubility4490 mg/LNot Available
logP-1.10SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility4.34 mg/mLALOGPS
logP-1.9ALOGPS
logP-1.3ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)4.63ChemAxon
pKa (Strongest Basic)9.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity46.33 m3·mol-1ChemAxon
Polarizability18.92 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.941
Blood Brain Barrier+0.9382
Caco-2 permeable-0.7271
P-glycoprotein substrateNon-substrate0.6557
P-glycoprotein inhibitor INon-inhibitor0.9789
P-glycoprotein inhibitor IINon-inhibitor0.8866
Renal organic cation transporterNon-inhibitor0.7982
CYP450 2C9 substrateNon-substrate0.893
CYP450 2D6 substrateNon-substrate0.8124
CYP450 3A4 substrateNon-substrate0.7612
CYP450 1A2 substrateNon-inhibitor0.9409
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9547
CYP450 3A4 inhibitorNon-inhibitor0.8438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9706
Ames testNon AMES toxic0.9162
CarcinogenicityNon-carcinogens0.8536
BiodegradationNot ready biodegradable0.7046
Rat acute toxicity1.6472 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9406
hERG inhibition (predictor II)Non-inhibitor0.8659
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0900000000-bccc9bd5f1637db7b6c7
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0900000000-67139ca9559173bf9859
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-9000000000-bfe6527f738e4c67eb2b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-bb175ef297a289e1936b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udr-0900000000-258d4493623d0ab7b415
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f79-0900000000-bc24764f394c6fee34fd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-006ecd4a58af763b087f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-012c52738f11970adb8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-8f0d390195aa406adb5d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uk9-0900000000-72f8d5cb88eda76dab56
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-3900000000-b634b4e7144ec6ffdc83
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ktn-9800000000-20c4131179b228ab3440
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ke-9300000000-dd9d44ed4f16961ed075
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-f9a7deaa778e9d893ee8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-4f85e6ac9fd91a3e3b81
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uk9-0900000000-d3a4c5658e343cf3cf8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-3900000000-712133d5b9eae1b27ffb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ktn-9800000000-c652847259e0851b428e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ke-9200000000-77e258cf26b045a7e46e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-bb0075e8b8166387ff3a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uk9-0900000000-9e92acbd730e00943058
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0pvs-9800000000-ba043efa192e3c526cab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aou-9000000000-f44876af37d1698389cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-1900000000-8304d09827a02dd8f392
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-9800000000-aa9f205e389c72aead8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-eb3bc990b07a9471ea6e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-6514211d36ec828dafb5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fk9-0900000000-fb527245013f4d56589f
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Amino fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Gamma amino acid or derivatives / Amino fatty acid / Fatty acyl / Amino acid / Carboxylic acid / Monocarboxylic acid or derivatives / Organopnictogen compound / Primary amine / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
gamma-amino acid (CHEBI:42797)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Maneuf YP, Luo ZD, Lee K: alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Semin Cell Dev Biol. 2006 Oct;17(5):565-70. Epub 2006 Sep 24. [PubMed:17067834]
  2. Hota D, Bansal V, Pattanaik S: Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):443-6. [PubMed:17982508]
  3. Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8. [PubMed:16899342]
  4. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25. [PubMed:18299583]
  5. Hoffmann U, Dilekoz E, Kudo C, Ayata C: Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab. 2010 Sep;30(9):1588-92. doi: 10.1038/jcbfm.2010.92. Epub 2010 Jun 30. [PubMed:20588320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Hota D, Bansal V, Pattanaik S: Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):443-6. [PubMed:17982508]
  2. Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8. [PubMed:16899342]
  3. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25. [PubMed:18299583]
  4. Hoffmann U, Dilekoz E, Kudo C, Ayata C: Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab. 2010 Sep;30(9):1588-92. doi: 10.1038/jcbfm.2010.92. Epub 2010 Jun 30. [PubMed:20588320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. Cheng JK, Chen CC, Yang JR, Chiou LC: The antiallodynic action target of intrathecal gabapentin: Ca2+ channels, KATP channels or N-methyl-d-aspartic acid receptors? Anesth Analg. 2006 Jan;102(1):182-7. [PubMed:16368827]
  2. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25. [PubMed:18299583]
  3. Hoffmann U, Dilekoz E, Kudo C, Ayata C: Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab. 2010 Sep;30(9):1588-92. doi: 10.1038/jcbfm.2010.92. Epub 2010 Jun 30. [PubMed:20588320]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Purine nucleoside binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
ADORA1
Uniprot ID
P30542
Uniprot Name
Adenosine receptor A1
Molecular Weight
36511.325 Da
References
  1. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G: Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol. 2004 May 3;491(2-3):137-48. [PubMed:15140630]
  2. Zuchora B, Wielosz M, Urbanska EM: Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. Eur Neuropsychopharmacol. 2005 Jan;15(1):85-93. [PubMed:15572277]
  3. Kralic JE, Criswell HE, Osterman JL, O'Buckley TK, Wilkie ME, Matthews DB, Hamre K, Breese GR, Homanics GE, Morrow AL: Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005 Mar;115(3):774-9. [PubMed:15765150]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Shimoyama M, Shimoyama N, Hori Y: Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain. 2000 Apr;85(3):405-14. [PubMed:10781913]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled gaba receptor activity
Specific Function
Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coup...
Gene Name
GABBR1
Uniprot ID
Q9UBS5
Uniprot Name
Gamma-aminobutyric acid type B receptor subunit 1
Molecular Weight
108319.4 Da
References
  1. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE: Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol. 2001 Jan;59(1):144-52. [PubMed:11125035]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled gaba receptor activity
Specific Function
Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coup...
Gene Name
GABBR2
Uniprot ID
O75899
Uniprot Name
Gamma-aminobutyric acid type B receptor subunit 2
Molecular Weight
105820.52 Da
References
  1. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE: Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol. 2001 Jan;59(1):144-52. [PubMed:11125035]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
L-valine transaminase activity
Specific Function
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.
Gene Name
BCAT1
Uniprot ID
P54687
Uniprot Name
Branched-chain-amino-acid aminotransferase, cytosolic
Molecular Weight
42965.815 Da
References
  1. Goto M, Miyahara I, Hirotsu K, Conway M, Yennawar N, Islam MM, Hutson SM: Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin. J Biol Chem. 2005 Nov 4;280(44):37246-56. Epub 2005 Sep 1. [PubMed:16141215]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:47